Literature DB >> 34531959

Identification, Synthesis, and Characterization of a Major Circulating Human Metabolite of TRPV4 Antagonist GSK2798745.

Joseph E Pero1, John J McAtee1, David J Behm1, Jacques Briand1, Grazyna Graczyk-Millbrandt1, Karl Erhard1, Andrew D Roberts1, Ralph A Rivero1, Dennis A Holt1, Brian G Lawhorn1.   

Abstract

GSK2798745, an antagonist of the transient receptor potential vanilloid 4 (TRPV4) ion channel, was recently investigated in clinical trials for the treatment of cardiac and respiratory diseases. Human plasma and urine samples collected from healthy volunteers following oral administration were analyzed to identify circulating and excreted metabolites of the parent drug. One major circulating metabolite (1) was found in pooled human plasma samples, accounting for approximately half of the observed drug-related material. Isolation of metabolite 1 from urine samples followed by MS and NMR studies led to a putative structural assignment of 1 where hydroxylation of GSK2798745 occurred on the central ring, producing a penta-substituted cyclohexane structure containing three stereocenters. Two unique chemical syntheses of the proposed structure were developed to confirm the identity of metabolite 1 and provide access to gram quantities for biological characterization.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34531959      PMCID: PMC8436415          DOI: 10.1021/acsmedchemlett.1c00406

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  14 in total

Review 1.  Preclinical in vivo ADME studies in drug development: a critical review.

Authors:  Mario Pellegatti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-01-17       Impact factor: 4.481

2.  Total synthesis of kinamycins C, F, and J.

Authors:  K C Nicolaou; Hongming Li; Andrea L Nold; Doron Pappo; Achim Lenzen
Journal:  J Am Chem Soc       Date:  2007-08-04       Impact factor: 15.419

Review 3.  Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.

Authors:  R Scott Obach
Journal:  Pharmacol Rev       Date:  2013-02-13       Impact factor: 25.468

4.  Total synthesis of N-methylwelwitindolinone D isonitrile.

Authors:  Vikram Bhat; Kevin M Allan; Viresh H Rawal
Journal:  J Am Chem Soc       Date:  2011-03-29       Impact factor: 15.419

Review 5.  Recent advances in TRPV4 agonists and antagonists.

Authors:  Brian G Lawhorn; Edward J Brnardic; David J Behm
Journal:  Bioorg Med Chem Lett       Date:  2020-02-08       Impact factor: 2.823

6.  Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

Authors:  Carl A Brooks; Linda S Barton; David J Behm; Hilary S Eidam; Ryan M Fox; Marlys Hammond; Tram H Hoang; Dennis A Holt; Mark A Hilfiker; Brian G Lawhorn; Jaclyn R Patterson; Patrick Stoy; Theresa J Roethke; Guosen Ye; Steve Zhao; Kevin S Thorneloe; Krista B Goodman; Mui Cheung
Journal:  ACS Med Chem Lett       Date:  2019-07-15       Impact factor: 4.345

7.  Catalytic asymmetric conjugate addition of nitroalkanes to cycloalkenones.

Authors:  S Hanessian; V Pham
Journal:  Org Lett       Date:  2000-09-21       Impact factor: 6.005

8.  Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial.

Authors:  Glenn M Stewart; Bruce D Johnson; Dennis L Sprecher; Yogesh N V Reddy; Masaru Obokata; Steven Goldsmith; Brad Bart; Anna Oughton; Christina Fillmore; David J Behm; Barry A Borlaug
Journal:  Eur J Heart Fail       Date:  2020-03-30       Impact factor: 15.534

9.  Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4).

Authors:  Edward J Brnardic; Guosen Ye; Carl Brooks; Carla Donatelli; Linda Barton; Jeff McAtee; Robert M Sanchez; Arthur Shu; Karl Erhard; Lamont Terrell; Grazyna Graczyk-Millbrandt; Yanan He; Melissa H Costell; David J Behm; Theresa Roethke; Patrick Stoy; Dennis A Holt; Brian G Lawhorn
Journal:  J Med Chem       Date:  2018-10-18       Impact factor: 7.446

10.  An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.

Authors:  Kevin S Thorneloe; Mui Cheung; Weike Bao; Hasan Alsaid; Stephen Lenhard; Ming-Yuan Jian; Melissa Costell; Kristeen Maniscalco-Hauk; John A Krawiec; Alan Olzinski; Earl Gordon; Irina Lozinskaya; Lou Elefante; Pu Qin; Daniel S Matasic; Chris James; James Tunstead; Brian Donovan; Lorena Kallal; Anna Waszkiewicz; Kalindi Vaidya; Elizabeth A Davenport; Jonathan Larkin; Mark Burgert; Linda N Casillas; Robert W Marquis; Guosen Ye; Hilary S Eidam; Krista B Goodman; John R Toomey; Theresa J Roethke; Beat M Jucker; Christine G Schnackenberg; Mary I Townsley; John J Lepore; Robert N Willette
Journal:  Sci Transl Med       Date:  2012-11-07       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.